Showing results (181-190 of 2,280) with videos related to
Sort By:
Pageof 228
HIV Medicine|May 12, 2015
Pulmonary hypertension in HIV infection: a prospective echocardiographic studyC Schwarze-Zander, S Pabst, C Hammerstingl, et al.HIV Medicine|May 12, 2015
Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumoniaL A Barakat, M Juthani-Mehta, H Allore, et al.HIV Medicine|May 12, 2015
Pharmacokinetics of tenofovir during pregnancy and postpartumB M Best, S Burchett, H Li, et al.HIV Medicine|May 12, 2015
Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across EuropeM Mansfeld, A Skrahina, L Shepherd, et al.HIV Medicine|May 19, 2015
Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activationM Vassallo, J Durant, C Lebrun-Frenay, et al.HIV Medicine|July 16, 2015
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirD A Wohl, L Bhatti, C B Small, et al.HIV Medicine|July 16, 2015
HIV encephalopathy: glial activation and hippocampal neuronal apoptosis, but limited neural repairS C Tauber, O Staszewski, M Prinz, et al.HIV Medicine|August 2, 2016
Awareness and use of nonoccupational post-exposure prophylaxis among men who have sex with men in Vancouver, CanadaS Y Lin, N J Lachowsky, M Hull, et al.HIV Medicine|August 2, 2016
The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosisD Tominski, J Katchanov, D Driesch, et al.HIV Medicine|August 30, 2025
Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohortGerald Pierone, Laurence Brunet, Jennifer S Fusco, et al.Pageof 228